ArticleMolecular oncology2019

Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.

Purusottam Mohapatra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.